Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE000A3E5EG5
Fri, 22.12.2023
PAION AG
PAION AG: Sale of the business operations
Aachen (Germany), 22 December 2023 - The Specialty Pharma Company PAION AG (ISIN DE000A3E5EG5; Frankfurt Stock Exchange, PA8) announces that PAION AG and its German subsidiary, PAION Deutschland GmbH, with the approval of the preliminary insolvency administrator of PAION AG and PAION Deutschland GmbH, [ … ]
Wed, 22.11.2023
PAION AG
PAION AG CHANGES FROM PRIME STANDARD TO GENERAL STANDARD
Aachen, 22. November 2023 - The Specialty Pharma Company PAION AG (ISIN DE000A3E5EG5; Frankfurt Stock Exchange: PA8) announces that the stock exchange listing of PAION AG will be changed from the Prime Standard to the General Standard of the regulated market of the Frankfurt Stock Exchan [ … ]
Tue, 21.11.2023
PAION AG
PAION AG SIGNS STRATEGIC COOPERATION AGREEMENT WITH YICHANG HUMANWELL
Aachen, Germany, 21 November 2023 - The Specialty Pharma Company PAION AG (ISIN DE000A3E5EG5; Frankfurt Stock Exchange: PA8) announces the signing of a Memorandum of Understanding ("MOU") on a strategic cooperation with Yichang Humanwell at the China Innovation Conference. T [ … ]
Tue, 31.10.2023
PAION AG
PAION AG HAS FILED FOR THE OPENING OF INSOLVENCY PROCEEDINGS - PRELIMINARY INSOLVENCY ADMINISTRATOR APPOINTED
Aachen (Germany), 31 October 2023 - The specialty pharma company PAION AG (ISIN DE000A3E5EG5; Frankfurt Stock Exchange, Prime Standard: PA8) announces that, in accordance with the ad hoc announcement dated October 26, 2023, it filed fo [ … ]
Fri, 20.10.2023
PAION AG
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.
CORPORATE NEWS
PAION AG to issue approximately 4.8 million shares at EUR 1.90 per share in capital increase with subscription rights
Aachen, 20 October 2 [ … ]
Fri, 13.10.2023
PAION AG
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.
CORPORATE NEWS
PAION AG announces fully underwritten rights issue with target gross proceeds of EUR 10 million
Two investors have committed to backstop th [ … ]
Thu, 28.09.2023
PAION AG
PAION ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION FOR REMIMAZOLAM BY ITS LICENSEE MUNDIPHARMA IN JAPAN
Aachen, Germany, 28. September 2023 – PAION AG (ISIN DE000A3E5EG5; Frankfurt Stock Exchange, Prime Standard: PA8), a specialty pharmaceutical company with innovative compounds for use in outpatient and hospital sedation, anesthesia and critical [ … ]
Thu, 31.08.2023
PAION AG
PAION receives UK MHRA approval of Byfavo® (remimazolam) for the induction and maintenance of general anesthesia in adults
Aachen (Germany), 31 August 2023 - PAION AG (ISIN DE000A3E5EG5; Frankfurt Stock Exchange, Prime Standard: PA8), a specialty pharmaceutical company with innovative compounds for use in outpatient and in-hospital sedation, a [ … ]
Wed, 30.08.2023
PAION AG
PAION AG reports financial results for the First Half-Year 2023
Byfavo® approval by European Commission for general anesthesia in April 2023, launch followed in August 2023
Hana Pharm received approval for Byfavo® in general anesthesia in the Philippines in July 2023
TTY Biopharm filed in general anesthesia in Taiwan in March 2023
Combined [ … ]
Tue, 22.08.2023
PAION AG
PAION launches Byfavo® (remimazolam) in the first European country for General Anesthesia
Byfavo® is now commercially available in the Netherlands for the use in general anesthesia
PAION will launch Byfavo® with its distribution partners in a staggered manner by country
PAION estimates that approximately 30 million surgeries are performed un [ … ]